ONCAlert | 2017 San Antonio Breast Cancer Symposium

Dr. Jean Hoffman-Censits on the Future of Atezolizumab in Bladder Cancer

Jean Hoffman-Censits, MD
Published Online:2:29 PM, Fri March 4, 2016


Jean Hoffman-Censits, MD, medical oncologist, director, Multidisciplinary Genitourinary Oncology Center, Thomas Jefferson University Hospital, discusses the potential future of the investigational PD-L1 inhibitor atezolizumab. Hoffman-Censits says atezolizumab has recently undergone a phase II clinical trial for patients with bladder cancer who failed platinum-based chemotherapy. 

She adds that due to atezolizumab being a targeted agent, all patients submitted tumor tissue prior to the study to determine if PD-L1 was being expressed or not. She says this presence is important for the evaluation of the outcomes of patients once the trial has completed. Hoffman-Censits says the objective response rate in the phase II trial was 15% and patients who over-expressed PD-L1 had an objective response rate of 26%.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.